Eli Lilly and Co., US5324571083

Lam Research stock rises on Taiwan approval and a $301.90 close

Published on 09/01/2026 at 07:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lam Research stock has a fresh market catalyst after Taiwan approved a NT$9.835 billion investment, while the shares last closed at $301.90 with a $377.77 billion market cap.

Wissenschaftler im sterilen Pharma-Labor mit Edelstahl-Bioreaktoren und Laborgeräten
Fotorealistisches Pharma-Labor zeigt Eli Lilly and Company mit ISIN US5324571083 in moderner Forschungsumgebung symbolisch, Illustration mit AI erstellt.

Lam Research stock (ISIN US5324571083) has a fresh catalyst after Taiwan approved a NT$9.835 billion investment tied to the company, and the shares last closed at $301.90 with a $377.77 billion market cap as of August 30, 2026.

The Taiwan review board approval, reported on September 1, 2026, gives investors a concrete policy-and-capex angle to watch as Lam Research expands its regional footprint.

Taiwan approval

The investment item was approved on August 31, 2026 and was valued at NT$9.835 billion, or about US$310 million. That is the cleanest current catalyst in the available tape and it is large enough to matter for a semiconductor equipment name.

For context, Lam Research's most recent quoted close was $301.90, and the stock's market value was listed at $377.77 billion on August 30, 2026. The combination of a near-record market value and a new Taiwan approval keeps the focus on regional manufacturing exposure rather than on a broad market narrative.

Latest operating readout

Lam Research's latest reported quarter visible in the available results is the March quarter, where a recent analysis said growth was strong and margins were on the rise. The same source framed the stock around a 300% rally, which gives a useful historical comparison for how much the share price has already re-rated.

Consensus data in the current results points to an average rating of Moderate Buy and a consensus price target of $357.31, while another market summary put the latest close at $301.90. That gap between the close and the consensus target is one reason the name still draws active coverage.

Product angle

Lam Research's wafer fabrication equipment, especially etch and deposition systems, remains the core product set behind the Taiwan and foundry exposure. Those tools sit at the center of advanced chip manufacturing, which is why regional investment decisions can move the stock's narrative quickly.

Shares and valuation

The shares closed at $301.90 on August 30, 2026, with volume of 8.04 million shares and a market cap of $377.77 billion. A separate market snapshot also showed the stock up 76.12% for the year, which highlights how much of the move is already in the price.

Fact box

Company: Lam Research Corporation
ISIN: US5324571083
Ticker: LRCX
Exchange: Nasdaq
Sector / Industry: Information Technology / Semiconductor Equipment
Index membership: Nasdaq-100

Disclaimer...

en | US5324571083 | ELI LILLY AND CO. | boerse | 70033725 | bgmi